目的 探討黃葵膠囊聯(lián)合貝前列素鈉緩釋片治療慢性腎功能衰竭維持性血液透析的臨床療效。方法 選取2022年10月—2024年11月在恩施州中心醫(yī)院就診的慢性腎功能衰竭維持性血液透析的患者共計90例，按隨機數(shù)字表法分為對照組和治療組，每組45例。對照組早晚餐后口服貝前列素鈉緩釋片，1片/次。治療組在對照組基礎(chǔ)上口服黃葵膠囊，5粒/次，3次/d。兩組患者連續(xù)治療8周。比較兩組臨床療效、日常生活能力、腎功能指標(biāo)和血清炎癥因子。結(jié)果 對照組患者的總有效率為68.89%，治療組患者的總有效率為86.67%，組間比較差異顯著（P＜0.05）。治療后，兩組的日常生活能力量表（ADL）評分顯著升高（P＜0.05），且治療組的ADL評分高于對照組（P＜0.05）。治療后，兩組的腎小球濾過率（GFR）明顯升高，肌酐（Scr）、胱抑素C（Cys-C）、β2-微球蛋白（β2-MG）明顯降低（P＜0.05）；治療后，治療組的GFR高于對照組，Scr、Cys-C、β2-MG低于對照組（P＜0.05）。治療后，兩組的血清腎損傷分子-1（KIM-1）、親環(huán)素A（CyPA）、轉(zhuǎn)化生長因子-β1（TGF-β1）水平降低（P＜0.05）；治療后，治療組的血清KIM-1、CyPA、TGF-β1水平低于對照組（P＜0.05）。結(jié)論 黃葵膠囊聯(lián)合貝前列素鈉緩釋片可提高慢性腎功能衰竭維持性血液透析的臨床療效，通過減輕腎組織炎性損傷以保護殘余腎功能，提高日常生活能力。

Objective To explore the clinical efficacy of Huangkui Capsules combined with Beraprost Sodium Sustained-release Tablets in treatment of chronic renal failure and maintenance hemodialysis. Methods 90 Patients with chronic renal failure undergoing maintenance hemodialysis in The Central Hospital of Enshi Tujia and Miao Automomous Prefectur from October 2022 to November 2024 were divided into control group and treatment group according to the random number table method, 45 cases in each group. Patients in the control group took Beraprost Sodium Sustained-release Tablets orally after breakfast and dinner, 1 tablets/time. Patients in the treatment group took Huangkui Capsules orally on the basis of the control group, 5 capsules/time, 3 times daily. Patients in two groups were treated continuously for 8 weeks. The clinical efficacy, daily living ability, renal function indicators, and serum inflammatory factors were compared between two groups. Results The total effective rate (68.89%) of treatment in the control group was lower than 86.67% in the treatment group, with significant difference between two groups (P < 0.05). After treatment, ADL scores of two groups were significantly increased (P < 0.05), and ADL scores in the treatment group were higher than those in the control group (P < 0.05). After treatment, GFR in both groups were significantly increased, but Scr, Cys-C, and β2-MG were significantly decreased (P < 0.05). After treatment, GFR in the treatment group was higher than that of the control group, while Scr, Cys-C, and β2-MG were lower than those in the control group (P < 0.05). After treatment, serum levels of KIM-1, CyPA, and TGF-β1 in both groups were decreased (P < 0.05), and serum levels of KIM-1, CyPA, and TGF-β1 in the treatment group were lower than those in the control group (P < 0.05). Conclusion Huangkui Capsules combined with Beraprost Sodium Sustained-release Tablets can improve the efficacy of chronic renal failure and maintenance hemodialysis, protect residual renal function by reducing inflammatory damage of renal tissue, and improve daily living ability.

R983

烏魯木齊市衛(wèi)生局科學(xué)技術(shù)計劃項目（201618）